Have you and your family talked about the importance of knowing your family's medical history?
Did you know that 3% of all colorectal cancers are due to a syndrome called Lynch syndrome? Having Lynch syndrome puts you at an 80% increased risk of developing colorectal cancer.
This webinar will focus more about Lynch Syndrome and other inherited syndromes as they relate to colorectal cancer.
Heather Hampel, a genetics counselor from Ohio State University will discuss the importance of knowing your family history. She'll talk about when, how and where to find a genetics counselor, and what is it you should discuss with them.
To share the knowledge from 2015 GI ASCO, Dr. Al Benson, one of FightCRC Medical Advisory Board members, and Andi Dwyer discuss key highlights as they pertain to colorectal cancer from the symposium and what they mean for patients.
In this webinar, Fight CRC Medical Advisory Board member, Heather Hampel, MS, LGC, will discuss the major sub-types of hereditary colon cancer, the types of genetic tests that by be useful for you and your family, and what to do with your test results.
At our October webinar we spent time reviewing the importance of family history. In this webinar, we will discuss genetic and familial syndromes that are specific to colorectal cancer. We will discuss what you might look for in your family history and think about implications for prevention and management of the colorectal cancer syndromes based on this information!
About our Speakers:
Lisa Ku, MS, CGC | Certified Genetic Counselor at the University of Colorado.
Lisen Axell, MS, CGC | Certified Genetic Counselor at the University of Colorado.
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...UCLA
A germline microRNA binding site-disrupting variant, the KRAS-variant (rs61764370), is associated with an increased risk of developing several cancers. Because this variant is most strongly associated with ovarian cancer risk in patients from hereditary breast and ovarian families (HBOC), and with the risk of premenopausal triple negative breast cancer, we evaluated the association of the KRAS-variant with women with personal histories of both breast and ovarian cancer, referred to as double primary patients.
Genetic counselor, Heather Herrmann, will dive in to the topic of Lynch Syndrome & CRC. Heather has enjoyed working in both pediatric genetics and cancer genetics throughout her career. She has focused the last eight years in the area of hereditary cancer syndromes and hereditary cancer risk assessment.
To share the knowledge from 2015 GI ASCO, Dr. Al Benson, one of FightCRC Medical Advisory Board members, and Andi Dwyer discuss key highlights as they pertain to colorectal cancer from the symposium and what they mean for patients.
In this webinar, Fight CRC Medical Advisory Board member, Heather Hampel, MS, LGC, will discuss the major sub-types of hereditary colon cancer, the types of genetic tests that by be useful for you and your family, and what to do with your test results.
At our October webinar we spent time reviewing the importance of family history. In this webinar, we will discuss genetic and familial syndromes that are specific to colorectal cancer. We will discuss what you might look for in your family history and think about implications for prevention and management of the colorectal cancer syndromes based on this information!
About our Speakers:
Lisa Ku, MS, CGC | Certified Genetic Counselor at the University of Colorado.
Lisen Axell, MS, CGC | Certified Genetic Counselor at the University of Colorado.
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...UCLA
A germline microRNA binding site-disrupting variant, the KRAS-variant (rs61764370), is associated with an increased risk of developing several cancers. Because this variant is most strongly associated with ovarian cancer risk in patients from hereditary breast and ovarian families (HBOC), and with the risk of premenopausal triple negative breast cancer, we evaluated the association of the KRAS-variant with women with personal histories of both breast and ovarian cancer, referred to as double primary patients.
Genetic counselor, Heather Herrmann, will dive in to the topic of Lynch Syndrome & CRC. Heather has enjoyed working in both pediatric genetics and cancer genetics throughout her career. She has focused the last eight years in the area of hereditary cancer syndromes and hereditary cancer risk assessment.
- Were you diagnosed with colon or rectal cancer before the age of 50?
- Was anyone in your family diagnosed with colon cancer before the age of 50?
- Was anyone in your family diagnosed with uterine (endometrial) cancer before the age of 50?
- Are there cancers across several generations on one side of your family?
If you answered YES to just one of these questions, it's time to talk turkey about Lynch syndrome.
Lynch syndrome is an inherited genetic mutation, and having it increases your chance of getting colorectal cancer to 80%. Unfortunately, nearly every person living with Lynch syndrome is completely unaware of it.
Lynch syndrome also puts you at higher risk for brain, breast, kidney, melanoma, ovarian, pancreas, small bowel, stomach, or uterine/endometrial cancers. Knowledge is power and will help your medical team act more aggressively with their screening measures.
Brian Mansfield, a music critic for USA Today, didn't know he had Lynch syndrome until he was diagnosed with colorectal cancer earlier this year at the age of 48. After his diagnosis, he began talking with his family about their health history, "then the family tree lit up like a Christmas tree." Brian is chronicling his journey through a weekly USA Today online column, "My Semicolon Life."
Join national patient advocacy group Fight Colorectal Cancer as we host Brian and his doctor, Dr. Bill Harb, a colorectal surgeon at Cumberland Surgical Associates, along with Associate Director of Human Genetics at Ohio State University Heather Hampel as they tell you more about Lynch syndrome and how to dig into the medical mystery that may be lurking within your family tree. With the holidays coming up, never has there been a more appropriate time to talk turkey...and Lynch syndrome.
**Fight Colorectal Cancer thanks Can't Stomach Cancer, the Colon Club, Kidney Cancer Association, Myriad Genetics, and Ovarian Cancer National Alliance for their assistance with this webinar.**
On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Many important topics to the ovarian cancer community were discussed, including novel clinical trial designs, biomarkers, and new classes of agents such as immunotherapies.
Dr. Stephanie Blank and Dr. Melissa Frey update us on the latest developments in ovarian cancer research and treatment from the annual conference of the Society of Gynecologic Oncology. Dr. Blank is a gynecologic oncologist at Perlmutter Cancer Center at NYU Langone Medical Center and an associate professor at NYU School of Medicine. Dr. Frey is a Gynecological Oncology Fellow at NYU Langone Medical Center.
The incidence of cancer has been rising alarmingly for the last few decades. In India, more than 1200 cancer deaths are reported every day. Cancer can be removed from the body by surgery, provided it is detected early enough when the tumour is localised. Although it is extremely difficult to detect cancer in such an early stage, still the most important step in our fight against cancer remains its early detection.
For more information: www.cancertame.com
Companion slideshow for polyppolyp.com (Familial adenomatous polyposis)Douglas Riegert-Johnson
A companion slideshow to the polypolyp.com website. The website is designed to assist in polyposis care, education and documentation. (c) 2014 Douglas Riegert-Johnson.
- Were you diagnosed with colon or rectal cancer before the age of 50?
- Was anyone in your family diagnosed with colon cancer before the age of 50?
- Was anyone in your family diagnosed with uterine (endometrial) cancer before the age of 50?
- Are there cancers across several generations on one side of your family?
If you answered YES to just one of these questions, it's time to talk turkey about Lynch syndrome.
Lynch syndrome is an inherited genetic mutation, and having it increases your chance of getting colorectal cancer to 80%. Unfortunately, nearly every person living with Lynch syndrome is completely unaware of it.
Lynch syndrome also puts you at higher risk for brain, breast, kidney, melanoma, ovarian, pancreas, small bowel, stomach, or uterine/endometrial cancers. Knowledge is power and will help your medical team act more aggressively with their screening measures.
Brian Mansfield, a music critic for USA Today, didn't know he had Lynch syndrome until he was diagnosed with colorectal cancer earlier this year at the age of 48. After his diagnosis, he began talking with his family about their health history, "then the family tree lit up like a Christmas tree." Brian is chronicling his journey through a weekly USA Today online column, "My Semicolon Life."
Join national patient advocacy group Fight Colorectal Cancer as we host Brian and his doctor, Dr. Bill Harb, a colorectal surgeon at Cumberland Surgical Associates, along with Associate Director of Human Genetics at Ohio State University Heather Hampel as they tell you more about Lynch syndrome and how to dig into the medical mystery that may be lurking within your family tree. With the holidays coming up, never has there been a more appropriate time to talk turkey...and Lynch syndrome.
**Fight Colorectal Cancer thanks Can't Stomach Cancer, the Colon Club, Kidney Cancer Association, Myriad Genetics, and Ovarian Cancer National Alliance for their assistance with this webinar.**
On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Many important topics to the ovarian cancer community were discussed, including novel clinical trial designs, biomarkers, and new classes of agents such as immunotherapies.
Dr. Stephanie Blank and Dr. Melissa Frey update us on the latest developments in ovarian cancer research and treatment from the annual conference of the Society of Gynecologic Oncology. Dr. Blank is a gynecologic oncologist at Perlmutter Cancer Center at NYU Langone Medical Center and an associate professor at NYU School of Medicine. Dr. Frey is a Gynecological Oncology Fellow at NYU Langone Medical Center.
The incidence of cancer has been rising alarmingly for the last few decades. In India, more than 1200 cancer deaths are reported every day. Cancer can be removed from the body by surgery, provided it is detected early enough when the tumour is localised. Although it is extremely difficult to detect cancer in such an early stage, still the most important step in our fight against cancer remains its early detection.
For more information: www.cancertame.com
Companion slideshow for polyppolyp.com (Familial adenomatous polyposis)Douglas Riegert-Johnson
A companion slideshow to the polypolyp.com website. The website is designed to assist in polyposis care, education and documentation. (c) 2014 Douglas Riegert-Johnson.
Each January, the best and brightest minds in colorectal cancer research meet at the Gastrointestinal Cancers Symposium. Fight Colorectal Cancer and the Colon Cancer Alliance are partnering to bring you the big news in colorectal cancer from the 2013 symposium.
Join us to learn more about these topics:
- Can aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) keep cancer from returning?
- The relationship of body mass index (BMI) and exercise in colorectal cancer
- What scientists are learning about how your immune system can fight cancer
- The latest on what biomarkers can tell us about your cancer
- Rectal cancer treatment that is based on your biological make-up
The webinar will be led by Dr. Richard Goldberg, an internationally renowned gastrointestinal oncologist who specializes in colorectal cancer. He is a tenured professor in the Department of Internal Medicine at The Ohio State University and serves as physician-in-chief at Ohio State’s Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
June is cancer awareness month at Staff Management | SMX. To promote cancer awareness across our company, the Diversity Program Inclusion Council created this presentation to share statistics, cancer facts and testimonials from two Staff Management | SMX cancer survivors.
An introduction to week 1 of a free online course on enhancing prostate cancer care, delivered by Sheffield Hallam University in the UK (Oct-Nov 2014). Week 1 focuses on diagnosis.
Learning about health, family history and what information to collect is important! As we prepare for November as Health History Month, the holidays provide an excellent opportunity for families to share health history. This webinar will help you learn about colorectal cancer and cancer diagnosis, and what this means for you and your family. We’ll give you tools and resources that help you collect this important information.
http://fightcolorectalcancer.org/get-resources/webinar-series/
Surgeon General’s PerspectivesPublic Health Reports Janu.docxmabelf3
Surgeon General’s Perspectives
Public Health Reports / January–February 2015 / Volume 130 3
FAMILY HEALTH HISTORY:
USING THE PAST TO IMPROVE
FUTURE HEALTH
Boris D. Lushniak, MD, MPH, RADM, USPHS
More than a decade after completion of the Human
Genome Project,1 science has made substantial prog-
ress in the development of genomic tests for disease
diagnosis, prognosis, risk prediction, prevention, and
treatment. Yet, the simplest, most readily available,
and most affordable genomic tool for disease preven-
tion—the family health history—remains underused.
For almost all diseases of public health significance,
people with a family history of the disease have a higher
risk of developing the disease than people without a
family history. Even so, many people do not collect
family health history information and share it with
relatives2 or even with their health-care providers.
The year 2014 marked the 10th anniversary of the
Surgeon General’s Family Health History Initiative,
launched in 2004 by former Surgeon General Dr.
Richard Carmona.3 This initiative is a national cam-
paign to help families learn more about
their family health history. It provides a
free Web-based tool, My Family Health
Portrait, to help people collect, organize,
and record their family health informa-
tion. To highlight the importance of this
initiative, Dr. Carmona and later Surgeons
General have declared Thanksgiving as
Family Health History Day.
The collection of family health history
information is part of routine health-
care interactions and can inform clinical
decision making and preventive services.
Family health history is a part of many
screening and treatment guidelines and,
in some cases, can make a big difference in
the recommended age for screening. For
example, the U.S. Preventive Services Task
Force (USPSTF) strongly recommends
cholesterol screening beginning at age
35 years for men, but recommends early
cholesterol screening beginning at age
20 years for men and women who are at
increased risk of cardiovascular disease.4
A family history of cardiovascular disease
before 50 years of age in male relatives, or before 60
years of age in female relatives, is one of several fac-
tors that are used to define increased risk. Using these
recommendations, about 16% of young adults should
be screened earlier based solely on the estimated
prevalence of family history of early cardiovascular
disease among this age group.5 Likewise, the USPSTF
recommends screening for osteoporosis for women
aged 65 years or older, but earlier screening for women
aged 50–64 years with certain risk factors that include
parental history of fracture.6 Thus, a 55-year-old white
woman whose parent has had a hip fracture should
consider getting screened early because her 10-year
risk for major osteoporotic fracture is at least as great
as a 65-year-old white woman who has no additional
risk factors.
Several other USPSTF recommendat.
Colonoscopy Screening for Special Populationsalizain416
In a series of testimonials, a myriad of patients, previously diagnosed with colon cancer or not, defend the importance of getting Colonoscopy Screened.
For More detail Visit link below
http://gastrosymptoms.com/colonoscopy-screening-special-populations/
Dr. Murphy presents slides discussing general screening trends in the US, including how the US compares to other countries, different screening modalities, and differences in screening by:
-Age
-Gender
-Geography
-Race/Ethnicity
Looking to kick start your physical activity? Hoping to learn about how body movement can be a huge benefit for CRC patients and survivors? Curious about Climb for a Cure? Join this interactive webinar featuring Karia Coleman, MSK, personal trainer and athletic strength coach, and Fight CRC advocates as they discuss the importance, challenges, and joys of physical activity.
From bowel frequency, pain, and more, many colorectal cancer treatments lead to digestive side effects. Join this webinar with Dr. Cathy Eng to learn all about the digestive system, the side effects that are common due to CRC treatment, and how to manage those side effects.
Maine recently passed major colorectal cancer (CRC) policy at the state level. Join us to listen to their story and learn what worked well for CRC state advocacy!
Indiana just passed major colorectal cancer (CRC) policy this year. Join us to listen to their story and learn what worked well for CRC advocacy in Indiana!
Kentucky was one of the first states in the US to pass major colorectal cancer (CRC) policy. Join us to listen to their story and learn what worked well for CRC state advocacy!
Join Fight CRC in a webinar about biomarkers. In this session, Dr. Chris Lieu will focus the discussion on the NTRK biomarker, in addition to ctDNA, and Next-Generation Sequencing.
Join us as Eden Stotsky-Himelfarb, BSN, RN from Johns Hopkins Medicine discusses how to manage after a colorectal cancer diagnosis. In this session, she will cover understanding diagnoses, shared decision making, managing mental health, talking to family and colleagues, and more.
Some colorectal cancer treatments lead to side effects of the skin. In this webinar, Dr. Nicole LeBoeuf will discuss these specific side effects. She will talk about why they occur, how to prepare for them, and how to manage them.
Hear about the latest breaking colorectal cancer research! Fight CRC will be joined by Dr. Axel Grothey who will spend the hour detailing the research presented at the 2020 Gastrointestinal (GI) Cancers Symposium hosted by the American Society of Clinical Oncology.
Anticipating the end of life and making decisions about medical care at this time can be difficult and distressing for people with cancer and their loved ones. However, it is incredibly important to plan for the transition to end-of-life care.
In this webinar, we will discuss questions to ask when considering an end to curative treatment, what to expect with hospice and end-of-life care, a new medical care team, advance directives and healthcare proxies, options for pain, the role of caregivers and loved ones, and more.
In this webinar, Dr. Angela Nicholas, Dr. Chris Heery, and Wenora Johnson discuss all things clinical trials. Dr. Nicholas, a family practitioner and caregiver to her late husband, John MacCleod will dive into her experience searching for clinical trials along with advice to those currently searching, or planning on searching in the future. Dr. Heery, Chief Medical Officer for Precision Biosciences will spend time dispelling myths around clinical trials and challenges to enrollment, and Wenora Johnson, a stage III colon cancer survivor will describe the process and her point of view curating trials in the Fight CRC trial finder.
In this webinar, Dr. Popp will discuss everything you need to know about palliative care! This is an important webinar for colorectal cancer patients and their loved ones.
eeling worn out and exhausted all the time? You may be experiencing cancer-related fatigue. Tune in to this webinar to learn what cancer-related fatigue is, how to spot it, and how to manage it.
In this webinar, Dr. Azad discusses colorectal cancer recurrence. She addresses things to do to help reduce the risk of recurrence, in addition to what steps should be taken if colon or rectal cancer returns.
Join Fight CRC and Dr. Scott Kopetz to learn about the latest breaking colorectal cancer research from the American Society of Clinical Oncology 2019 Annual Conference.
May 2019 – What You Need to Know About Chemotherapy Induced Neuropathy WebinarFight Colorectal Cancer
Neuropathy is a common side effect for colorectal cancer patients. It is a side effect that can be incredibly challenging to manage, and can affect daily living. Join this informative webinar to learn all about neuropathy—why it happens, how to prepare for it, and methods to try and reduce its effects. This is an important webinar for all survivors and patients! Dana will speak from both the medical professional and patient angle, as she is a colon cancer survivor herself!
A cancer diagnosis and cancer treatment can be traumatic. An experience with cancer can lead to serious psychological distress that should be addressed. In this webinar, Schuyler Cunningham, Clinical Social Worker, talks about what trauma is, how to identify it, and what steps to take next.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Family First: What you need to know about family history, genetic testing, and colorectal cancer.
1. Welcome to Fight Colorectal Cancer’s
Webinar
Family First:
What you need to know about genetic testing,
family history& colorectal cancer
Our webinar will begin shortly.
2. Today’s Webinar:
1. Today’s Speaker: Heather Hampel, MS, CGC
2. Archived Webinars: FightColorectalCancer.org/Webinars
3. AFTER THE WEBINAR: expect an email with links to the
material. Also a survey on how we did, receive a Blue Star pin
when completed
4. Ask a question in the panel on the RIGHT SIDE of your screen
5. Follow along via Twitter – use the hashtag #CRCWebinar
3. Upcoming Webinar
Research News:
The latest news about Colorectal Cancer Research
& Treatment
Presented in partnership with the Colon Cancer Alliance
June 18, 2014
3pm EST / 2pm CT / 1pm MT / 12pm PT
Get information at FightColorectalCancer.org/Webinars
4. Funding Science
Established in 2006, our Lisa Fund has
raised hundreds of thousands of dollars
to directly support the innovative research
in treating late-stage colorectal cancer.
100% of the funds donated go
directly to
Late-stage colorectal cancer
research.
Learn more or donate:
FightColorectalCancer.org/LisaFund
5. Disclaimer
The information and services provided by Fight Colorectal
Cancer are for general informational purposes only. The
information and services are not intended to be
substitutes for professional medical advice, diagnoses, or
treatment.
If you are ill, or suspect that you are ill, see a doctor
immediately. In an emergency, call 911 or go to the
nearest emergency room.
Fight Colorectal Cancer never recommends or endorses
any specific physicians, products or treatments for any
condition.
7. Family First: What you need
to know about genetic
testing, family history &
colorectal cancer
Heather Hampel, MS, CGC
Professor, Division of Human Genetics
November 5, 2011
8. 8
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Most cancers are not inherited
5-10% hereditary10-15% familial
75-85% sporadic
9. 9
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Who is at high risk for cancer?
History is the key…
10. 10
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Family History
An important first step in risk
assessment for genetic diseases
and other hereditary health
conditions
11. 11
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Genetic Family History –
My Family Health Portrait
• “The family tree has become the most
important genetic test of all…”
• To help focus attention on the importance of family
health history, U.S. Surgeon General in cooperation
with other agencies within the U.S. Department of
Health and Human Services (HHS) has launched a
national public health campaign, called the U.S.
Surgeon General's Family History Initiative, to
encourage all American families to learn more about
their family health history. http://www.hhs.gov/familyhistory/
12. 12
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
My Family Health Portrait
• Americans know that family history is
important to health. A recent survey
found that 96 percent of Americans
believe that knowing their family history
is important. Yet, the same survey found
that only one-third of Americans have
ever tried to gather and write down their
family's health history.
http://www.hhs.gov/familyhistory/
13. 13
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
My Family Health Portrait
• Because family health history is such a
powerful screening tool, the Surgeon
General has created a new
computerized tool to help make it fun
and easy for anyone to create a
sophisticated portrait of their family's
health. http://www.hhs.gov/familyhistory/
14. 14
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
National Family History Day
• Thanksgiving is an annual National
Family History Day. Thanksgiving is the
traditional start of the holiday season for
most Americans.
• Whenever families gather, the Surgeon
General encourages them to talk about,
and to write down, the health problems
that seem to run in their family. Learning
about their family's health history may
help ensure a longer future together.
• http://www.hhs.gov/familyhistory/
15. 15
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Family history is a risk factor for
diseases throughout all stages of life
infants
children
adolescents
adults
older
adults
birth defects
blood
disorders
Alzheimer’s
disease
osteoporosis
cancer
heart
disease
diabetes
depression
asthma
autism
16. 16
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Taking a Family History
Obtain at least a three-generation
pedigree
Ask about all individuals in the family
and record:
Age at any diagnosis, age at and
cause of death
Any corrective surgeries
Associated congenital abnormalities
Record ethnicity and religious
background
Some cancer syndromes are more common
in individuals from certain ethnic groups
17. 17
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Three-Generation Pedigree
Colon cancer
dx 40
62
35
German/Polish English/Irish
Endometrial Cancer
dx 49
d. 72
d. 80
67 5565 Diabetes, dx
45 59
52
30
d. 70 d. 85
18. 18
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Family History Questionnaires
Name
Davis, John
Jones, Mary
Date of
Birth
2/1/40
4/9/42
Age at dx/
Type of
Cancer
CRC dx 48
Endometrial
dx 52
Date
of
Death
4/3/87
N/A
Hospital
U. Minn.
Franklin
Medical
center
19. 19
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Information to Obtain About
Affected Relatives
Current age
Age at and date of diagnosis/death
Type and number of colon polyps
Type and location of cancer
Primary cancer location vs. metastatic
cancer site
Hospital where treated
Environmental exposures (eg, sun)
20. 20
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Information to Obtain About
Unaffected Relatives
Current age
Health status and history of significant
illnesses
Presence of other physical findings
associated with syndromes
If deceased, cause of and age at death
21. 21
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
“Female” cancer
Ask about the presenting features
Detected by Pap smear – likely cervical cancer
Diagnosed due to heavy bleeding – likely
uterine/endometrial cancer
Bloated (looked 6 months pregnant) – likely ovarian
cancer
Ask about the treatment
Hysterectomy but ovaries left behind – probably not
ovarian cancer
No chemotherapy – probably NOT ovarian cancer
LEEP procedure or colposcopy – probably cervical
dysplasia or cancer
22. 22
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Unknown type of cancer
Request copies of medical records (pathology
reports are the key) from the hospital where the
relative was treated
If a family member makes the request, there will be a
charge for the records
If you physician or genetic counselor makes the
request, there will not be a charge for the records
Request death certificates
Can be obtained from the state department of health
relatively inexpensively
Can be obtained at www,vitalchek.com from any state
– arrive quickly, slightly more expensive
23. 23
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
High Risk Clues:
Cancer in 2 or more close relatives
(on same side of family)
Multiple generations affected
Early age at diagnosis
Multiple rare cancers (sebaceous skin cancer)
Multiple primary tumors (colon and uterus;
more than one colon cancer)
Multiple colon polyps (>10)
Patients with certain pathology findings
Abnormal IHC or MSI+ testing
24. 24
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
CAUTION
25. 25
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Family History can be unreliable
Many people do not know the details of their family
history.
Specific sites of tumors unknown
Ages of onset unknown
Historical information needs to be verified in order to
accurately assess risk.
Family size is getting smaller – can “hide”
susceptibility
Increased use of effective screening/prevention
options (i.e. colonoscopy) can prevent cancers that
would have occurred otherwise
26. 26
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Initial pedigree After review of records
Stomach
Ca
Prostate
problems
Bone Ca
d. 48
Breast Ca
dx 45
d. 48
Ovarian Ca
dx 43, d. 49
Prostate Ca
dx 50
27. 27
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Histories are dynamic
With the passage of time, additional diagnoses may
have been made.
These changes in diagnosis may affect the likelihood
of a hereditary cancer syndrome.
28. 28
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Initial History 2 years later
Colon Ca, 50
Colon Ca, 50
Endometrial
Ca, 44
Colon polyps, 48
29. 29
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Flowchart for Hereditary Colon Cancer
Differential Diagnosis
Presence of
>10 polyps
Type of polyps
Lynch syndrome
Familial Colorectal Cancer
syndrome type X
MUTYH-Associated Polyposis
Peutz-Jeghers syndrome
Juvenile Polyposis
Serrated Polyposis syndrome
Familial Adenomatous Polyposis
Attenuated FAP
MUTYH-Associated Polyposis
NoYes
AdenomatousHamartomatous
30. 30
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Hereditary Cancer Syndromes: Lynch
Syndrome & FAP
MLH1
PMS2
MSH2 MSH6 APC
31. 31
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Sporadic Inherited
• Later age at onset (60s or 70s)
• Little or no family history of cancer
• Single or unilateral tumors
•Early age at onset (<50)
•Multiple generations with
cancer
•Clustering of certain cancers
(i.e. breast/ovarian)
Normal gene
Somatic
mutation
Somatic
mutation
Germline
mutation
Somatic
mutation
32. 32
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Autosomal Dominant Inheritance
Carrier Parent Non-carrier Parent
Aa aa
Aa Aa aa aa
Carrier Carrier Non-carrier Non-carrier
1/2 1/2
33. 33
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Lynch Syndrome
Early but variable age
at CRC diagnosis
(~45 years)
Tumor site in
proximal colon
predominates
Extracolonic cancers:
endometrium, ovary,
stomach, urinary
tract, small bowel,
bile ducts, sebaceous
skin tumors
34. 34
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Amsterdam II criteria
• 3 or more relatives with verified HNPCC-
associated cancer in family
• Two or more generations
• One case a first-degree relative of the
other two
• One CRC dx <50
• FAP excluded
Vasen HFA et al. Gastroenterology. 116:1453, 1999
Does not include
ovarian, gastric, brain,
biliary tract or
pancreatic cancer
35. 35
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Bethesda Guidelines
Individual with CRC dx <50
Individual with synchronous or metachronous
CRC, or other HNPCC-associated tumors
regardless of age
Individual with CRC with MSI-H histology dx <60
Individual with CRC with >1 FDR with an
HNPCC-associated tumor, with one cancer dx
<50
Individual with CRC with >2 FDRs or SDRs with
an HNPCC-associated tumor, regardless of age
Umar A, et al. JNCI. 2004;96(4):261-268.
36. 36
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Lynch Syndrome Cancer Risks (to 70)
Cancer Lynch syndrome General Public
Colon cancer 56-85% 5%
Endometrial cancer 35-60% 2%
Gastric cancer 13% 1%
Ovarian cancer 12% 1.5%
Small bowel, bladder,
ureter, renal pelvis, brain
<4% each <1% each
37. 37
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Lynch syndrome Surveillance Options
Lindor N et al. JAMA 2006;296:1507-17. & Vasen HFA et al. J Med Genet 2007;44:353-62.
Intervention Recommendation
Colonoscopy Every 1-2 y beginning at age 20-25 (MLH1 &
MSH2), or 30 (MSH6 & PMS2)
Endometrial sampling Every 1 y beginning at age 30-35
Transvaginal U/S Every 1 y beginning at age 30-35
Urinalysis with cytology Every 1-2 y beginning at age 30-35
History & Exam w/
review of systems
Every 1 y beginning at age 21
38. 38
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Case 1
39. 39
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Case 2
40. 40
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Clinical Features of FAP
Estimated penetrance
for adenomas >90%
Risk of extracolonic
tumors (upper GI,
desmoid, osteoma,
thyroid, brain, other)
CHRPE may be present
Untreated polyposis
leads to 100% risk of
cancer
41. 41
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
42. 42
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
43. 43
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Attenuated FAP
l Later onset (CRC ~age 50)
l Few colonic adenomas
l Not associated with CHRPE
l UGI lesions
l Associated with mutations at
5' and 3' ends of APC gene
44. 44
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
MUTYH-Associated Polyposis (MAP)
Recessive inheritance – carrier frequency high
Biallelic MYH mutations are found in:
96/1457 (6.6%) patients with >100 adenomas
233/3253 (7%) patients with 20-99 adenomas
37/970 (4%) patients with 10-19 adenomas
19/1147 (2%) patients with <10 adenomas
Y165C & G382D common in W.E. Caucasians
E466X in Eastern Indian families
Grover S et al. JAMA 2012;308:485-92.
45. 45
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
MUTYH-Associated Polyposis (MAP)
MYH mutations in CRC dx <50
8/1116 (0.7%) +
12/1238 (1%) +
4/64 (6.3%) +
Heterozygote risk
14/259 heterozygotes had adenomas vs 2/107
controls
2/50 obligate carrier parents had CRC – Expected
If there is a cancer risk for heterozygotes – LOW
Wang L et al. Gastroenterology 2004;127:9-16;
Croitoru S et al. J Natl Cancer Inst 2004;96:1631-4.
Balaguer et al. Clin Gastroenterol Hepatol 2007;5:379-87
46. 46
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
MAP Management
Colonoscopy every 2-3 y begin at 25-30 if negative
for polyps
Once polyps are found, colonoscopy and
polypectomy every 1-2 y
Subtotal colectomy or proctocolectomy depending
on adenoma density and distribution
Consider UGI endoscopy and side viewing
duodenoscopy begin at 30-35 and repeat depending
on findings
Annual physical examination
NCCN Guidelines for Colorectal Cancer Screening 2.2014
47. 47
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Who to test for FAP & MAP?
APC testing criteria
Personal history of >10 adenomas
Personal history of a desmoid tumor
Known APC mutation in family
MUTYH testing criteria
Personal history of >10 adenomas
Individual meeting SPS criteria with some adenomas
Known MUTYH mutations in family
Start testing with affected relative if possible
If affected relative is deceased, can test at-risk
relative but negative result is uninformative
Can test minors because cancer screening starts in
childhood
NCCN Guidelines for Colorectal Cancer Screening 2.2014
48. 48
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Moderate Risk Families
1-2 cases of a cancer in the family
Do not need referral for genetic counseling
Do need increased cancer surveillance
Generally the first degree relatives of a person with a
cancer are about twice as likely to develop that
same cancer than someone without that family
history
49. 49
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
50. 50
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Familial Colorectal Cancer Risks
Taylor, DP, Gastroenterology 2010;138:877-886.
51. 51
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Familial Colorectal Cancer Screening
Recommendations
FDR diagnosed <50 or 2 FDR dx at any age
Colonoscopy every 3-5 years beginning at age 40 (or 10
years before earliest dx of CRC
FDR diagnosed >50
Colonoscopy every 5 years beginning at age 50 (or 10
years before earliest dx of CRC
SDR diagnosed <50
Colonoscopy beginning at age 50 repeat depending on
findings
FDR with advanced adenoma(s)
Colonoscopy beginning at age 50 or age of onset repeat
depending on findings
Otherwise follow Average Risk recommendations
Colonoscopy every 10 years beginning at age 50
52. 52
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Family Healthlink
Interactive web tool that estimates risk by
reviewing patterns of cancer and heart disease
and related conditions in a family
10-15 min depending on the size of the family
No pedigree to view; no updating
Personalized risk assessment (pdf) to share with
healthcare providers
https://familyhealthlink.osumc.edu
53. 53
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Genetic Counseling
54. 54
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Genetic Counseling:
Purpose
Appreciate the way heredity contributes to
cancer
Understand an individual’s risk of
developing cancer
Understand the options for dealing with an
increased risk for cancer
Choose a course of action for managing
cancer risk that seems personally
appropriate (genetic testing, screening or
long-term follow up)
55. 55
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Genetic Counseling:
What happens
Collection of personal and family history
3 generation pedigree
Education and risk assessment
Options for genetic testing and medical
management
Discussion of risks, benefits and limitations
Screening/Chemoprevention/Prophylaxis
Follow-up
Provide psychosocial support
Family members
56. 56
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Genetic Testing:
Purpose
If the exact gene mutation can be identified in a
family, it can:
Diagnose the family with a specific cancer syndrome
Determine for which cancers the family is at risk
Determine a cancer surveillance & prevention plan
Allow at-risk family members to be tested
inexpensively and reliably
Relatives who inherit the mutation need to follow the
increased cancer surveillance & prevention plan
Relatives who do NOT inherit the mutation can follow
the American Cancer Society guidelines for cancer
screening in the general population
50 colonoscopies versus 3 colonoscopies
57. 57
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Genetic Testing:
What happens
Testing is most accurate when you begin by testing
a family member who has had cancer (or polyps)
If they test positive, the family has a diagnosis and a
known mutation for follow-up testing
If they test negative, the family history may or may not
still be hereditary but there is no known mutation for
follow-up testing
Many sites will start Lynch syndrome testing with a
screening test on the colon or endometrial tumor
Stored in a wax block at the hospital where you had
surgery
Genetic Testing is done using either a blood sample
or a saliva/mouthwash sample
58. 58
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Genetic Testing:
What happens
Costs:
Tumor screening tests $500-$1500
Genetic testing $1500/gene or $1500-4500/all genes
Known mutation testing $200 - $500
Results:
Can take anywhere from 2-12 weeks
May be given by telephone or in the setting of post-
test genetic counseling depending on center
59. 59
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Genetic Testing:
Informed Consent
Benefits
Know reason for cancers in family
Ability to determine who is and who is not at risk
Ability to be screened appropriately
Limitations
Variants of Uncertain Significance
Genes that have not been discovered yet
Risks
Bruise from blood draw
Psychological risks (guilt from passing gene onto
children, adjustment to testing positive, survival guilt
when testing negative)
Insurance discrimination
60. 60
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
GINA
Prevents health insurers from denying coverage,
adjusting premiums, or otherwise discriminating on the
basis of genetic information.
Group and self-insured policies
Insurers may not request that an individual undergo a
genetic test.
Employers cannot use genetic information to make
hiring, firing, compensation, or promotion decisions.
Sharply limits a health insurer's or employer's right to
request, require, or purchase someone's genetic
information.
61. 61
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Refer to an cancer genetic counselor near you
Find a Local Counselor from the NSGC
http://nsgc.org/p/cm/ld/fid=164
Find a Local Cancer Genetics expert from the NCI
http://www.cancer.gov/cancertopics/genetics/directory
Refer to a national telecounseling service
Informed DNA at http://www.InformedDNA.com
1-800-975-4819
How to find a genetic counselor near you
Heather Hampel
62. Question & Answer Time . . .
DONATE $10 NOW.
Text “FCRC” to 501501
(A $10 donation to Fight Colorectal Cancer will be
deducted from your cell phone bill. Message rates
apply.)
BECOME AN ADVOCATE.
Learn more at FightColorectalCancer.org/Advocacy
How can YOU help? Join us.
63. Contact Us
Fight Colorectal Cancer
1414 Prince Street, Suite 204
Alexandria, VA 22314
(703) 548-1225
Resource Line: 1-877-427-2111
www.FightColorectalCancer.org
facebook.com/FightCRC
twitter.com/FightCRC
youtube.com/FightCRC
pinterest.com/FightCRC
64. 64
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute
Resources
Heather Hampel
614-293-7240
Heather.Hampel@osumc.edu
Family HealthLink
https://familyhealthlink.osumc
.edu
Free, on-line tool that
assesses family history of
cancer and cardiovascular
disease